Publication | Closed Access

20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

Bone DiseaseAdvanced CancerMedicineCancer ManagementClinical TrialsMultiple MyelomaBreast CancerOsteoporosisCancer TreatmentOncologyRadiation OncologyOrthopaedic SurgeryHealth Sciences